TaiMed’s lead development program, the long-acting monoclonal antibody combination TMB-365/TMB-380, is designed for general HIV patients with virologically suppressed disease. The regimen offers once-every-two-month intravenous dosing (Q2M) and monthly subcutaneous self-injection (SC) potential. According to the latest update, the Phase 2b clinical trial achieved First Patient In (FPI) in December 2025, with an interim analysis planned for late 2026 or early 2027, and completion of Phase 2b in the 2nd half of 2027.
Compared with other long-acting competitors, TMB-365/TMB-380 demonstrates compelling differentiation:
1.No resistance screening required
Competing therapies (such as those from Gilead or ViiV) typically require viral sensitivity testing, with exclusion rates ranging from 28% to 50%. TaiMed’s antibody combination offers broad antiviral coverage and can be administered without resistance screening, significantly expanding patient eligibility.
2.Superior safety profile
Clinical data indicate lower rates of injection-site pain and serious adverse events compared with currently available therapies.
3.Significant market expansion potential
The target population is front-line HIV maintenance therapy that represents the majority of the HIV patient population, compared with only ~5% addressed by first-generation Trogarzo® for multi-drug resistant patient polulation. The peak sales potential estimated at USD 3–4 billion.
Beyond HIV, TaiMed is actively advancing its TMB-365-ADC (antibody–drug conjugate) platform, which management views as the company’s next major value inflection driver. Leveraging the high specificity of the TMB-365 monoclonal antibody, this platform enables precise targeting of CD4+ immune cells, delivering therapeutic payloads directly into disease-driving cells.
This technology supports two major strategic applications:
1.Precision HIV therapy
The ADC approach directly targets HIV reservoir cells, requiring less than 1% of the original drug dose, effectively suppressing viral replication while minimizing systemic toxicity.
2.Next-generation autoimmune disease treatment
Many autoimmune diseases are driven by overactivated CD4+ T cells. The TMB-365-IMMUNE ADC program enables targeted delivery of immunomodulatory agents, addressing key limitations of existing TNF or JAK inhibitors, which are associated with systemic immunosuppression, thrombosis, and other adverse effects.
TaiMed highlighted that the global autoimmune disease market is projected to reach USD 416.6 billion by 2033, more than seven times the size of the HIV market. CD4-driven autoimmune diseases—such as rheumatoid arthritis, multiple sclerosis, and Crohn’s disease—represent an estimated USD 80 billion market, and TaiMed has initiated development programs to address unmet needs in this space.
Based on TaiMed’s valuation model, the company is entering a critical inflection point for value creation. As Phase 2b data are expected to read out in 2026–2027, positive results would significantly reduce development risk and enhance the asset’s licensing value. The asset’s valuation is expected to increase from approximately USD 1.0 billion today to an estimated USD 2.3 billion. Following anticipated BLA approval in 2030, the valuation is expected to further increase substantially to approximately USD 9–12 billion.
Dr. Jimmy Chang, CEO of TaiMed Biologics, emphasized that the company is supported by its in-house GMP manufacturing capabilities and extensive CDMO collaboration experience. TaiMed will continue to aggressively advance its R&D programs while actively pursuing international licensing and co-development opportunities to maximize long-term shareholder value.
Contact CDMO Service